Germany

Germany is the hardest ownership regime in Europe and shows no sign of softening. Under §7 ApoG the operating licence belongs to a licensed Apotheker personally, with a maximum of four branches (Mehrbesitz cap). ABDA defended the rule vigorously in its January 2026 submission on the government's ApoVWG draft, objecting even to temporary PTA-led branch management as an erosion of the principle.

The ApoVWG passed the Bundestag on 22 May 2026. It expands PTA competencies, adds pharmacy services and eases rural branch rules, and does not touch either the Fremdbesitzverbot or the four-branch cap. Treat non-pharmacist pharmacy ownership in Germany as closed, not merely difficult.

What a non-pharmacist founder can do is run the brand, platform and prescriber-contracting layer as a separate company, with a licensed pharmacy dispensing. That is the structure every operator here uses.

The boundary is §11 ApoG: the Zuweisungsverbot, which bans arrangements that steer or reward prescription referrals. LG Frankfurt (28 May 2025) held that a platform defaulting a prescription to a designated partner pharmacy does not breach it, provided the patient makes an affirmative, disclosed choice and keeps a visible working alternative. Silently locking the patient to one pharmacy is the illegal version.

Separately, a 2024 Munich ruling found DocMorris's cooperation with its own telemedicine arm Teleclinic amounted to unlawful patient referral, the same legal theory that killed the Shop Apotheke / Zava contraceptive referral flow at the BGH in February 2023. Referral design is a live litigation area here, not a settled one.

Since the 2018 liberalisation, §7(4) MBO-Ä permits Fernbehandlung as sole contact where it is compatible with medical standards in the individual case. That is a case-by-case test, not a blanket permission, and for GLP-1s the courts have applied it strictly.

LG München I, 3 March 2025 (4 HK O 15458/24) enjoined a Netherlands-based online pharmacy advertising remote-prescribed weight-loss injections to German consumers, holding both that the advertising breached HWG §10 and that questionnaire-only remote treatment of obesity does not meet recognised medical standards, personal physician contact is required given the need for monitoring, bloods and side-effect management. OLG Köln (10 June 2022, 6 U 204/21) had reached the same conclusion three years earlier against a similar NL-platform arrangement.

Routing the prescriber through another EU country does not fix this: both cases were brought against non-German operations and German professional-standard reasoning was applied anyway, because the service targeted German consumers.

HWG §10 restricts advertising of prescription-only medicines to Fachkreise, doctors, dentists, vets, pharmacists. That is long-settled. What changed in 2026 is how far "advertising" now reaches.

On 26 March 2026 the BGH ruled in I ZR 74/25 (Wettbewerbszentrale v Bloomwell/Algeacare, a medical-cannabis telemedicine case but directly on point) that a platform describing the conditions a prescription drug class treats, and enabling a treatment request off the back of it, is itself unlawful public advertising, even without naming a product. The court expressly rejected the "we only connect patients to doctors" defence.

Read together with the Munich ruling, the corridor is narrow: a medically-branded weight-management programme whose drug-specific and price content sits behind a completed, medically adequate intake. Note also that marketing to healthcare professionals is entirely permitted, the ban protects the public, not the trade.

This is the single most consequential unresolved point in the German picture. The Arzneimittelpreisverordnung fixes a uniform pharmacy retail price for Rx drugs regardless of insurance status, which means a German-domiciled pharmacy cannot discount a private Mounjaro prescription. Price competition is structurally impossible domestically.

The ECJ's Deutsche Parkinson Vereinigung ruling (C-148/15, 2016) held Germany cannot enforce that fixed-price rule against mail-order pharmacies established in other member states, and a BGH decision in July 2025 reaffirmed it for Rx bonuses. That is why every DACH operator dispenses from the Netherlands.

But a separate 2024 Munich appellate ruling is reported to have upheld price binding against foreign senders as justified consumer protection, and the 2020 VOASG reinstated uniform pricing through social-insurance law for the GKV channel. These cannot both be fully right for the same category of sale. Until a German pharmaceutical lawyer resolves it, treat the price-freedom rationale for the Dutch route as unproven.

§34 Abs. 1 SGB V has excluded drugs used "überwiegend zur Erhöhung der Lebensqualität" from statutory reimbursement since 2004, and the G-BA formally applied it to Wegovy on 21 March 2024 with the qualifier "gilt nur für Gewichtsreduktion", the same molecule for an approved non-weight indication is still reimbursable. Novo Nordisk has registered lobbying activity aimed at amending §34, and a patient petition is running, but no repeal has happened and a June 2025 Sozialgericht ruling reportedly upheld the exclusion even with comorbidities present.

Structurally this is good news for a private operator: the German obesity market is cash-pay by statute.

Consumer prices (indicative, mid-2026): Mounjaro €206 (2.5mg), €277 (5mg), €383 (7.5/10mg), €489 (12.5/15mg). Wegovy about €172 up to 1mg, €236 at 1.7mg, €277 at 2.4mg, Novo cut the maintenance dose from €301.97 to €276.83 in April 2025 explicitly to defend the self-pay channel. A liraglutide generic, Nevolat (Zentiva), launched January 2026 at roughly €79–129/month but requires daily injection.

The European Commission granted EU-wide authorisation for the Wegovy pill on 15 July 2026, and Germany is the first EU country to launch it, in September 2026. That is the single most actionable date in the European picture: the largest telehealth-driven GLP-1 market in Europe gets a product that needs no cold chain, weeks from now.

Orforglipron has no EU approval yet, the MHRA authorised it on 10 August 2026, which covers the UK only.